BenevolentAI (previously Stratified Medical) is a leading artificial intelligence company that combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines.
BenevolentAI aims to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world’s 8,000 untreated diseases.
BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines.
BenevolentAI's unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases.
BenevolentAI has several successful collaborations with leading pharmaceutical organisations. They are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19.
BenevolentAI is backed by Temasek Holdings, Goldman Sachs, Woodford Investment Management, Lansdowne Partners, and others. The company has raised a total of $297M in funding to date. BenevolentAI was reportedly valued at $1B from a financing raised in Sep 2019.